FHTX - Company ID 0001822462
The table below shows Foghorn Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.27M | -$23.97M | -$29.34M | -$31.18M | $271.53M | -$23.15M |
| Capital expenditure | $0.00 | $28.00K | $101.00K | $636.00K | $247.00K | $1.79M |
| Investing cash flow | -$17.72M | $29.40M | $27.09M | $29.50M | -$159.41M | -$3.26M |
| Dividends paid | - | - | - |
Foghorn Therapeutics Inc. reported operating cash flow of -$86.10M for fiscal year 2025. That is up 14.2% from -$100.41M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$46.34M (FY 2019) to -$86.10M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $49.77M | $139.00K | $1.17M | $102.00K | $384.00K | $62.00K |